Fisher Asset Management LLC Buys Shares of 62,372 Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH)

Fisher Asset Management LLC acquired a new position in Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH - Free Report) during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor acquired 62,372 shares of the company's stock, valued at approximately $1,006,000. Fisher Asset Management LLC owned approximately 0.08% of Deciphera Pharmaceuticals at the end of the most recent quarter.

Several other hedge funds have also bought and sold shares of DCPH. Frazier Life Sciences Management L.P. lifted its position in shares of Deciphera Pharmaceuticals by 176.2% during the 4th quarter. Frazier Life Sciences Management L.P. now owns 1,021,800 shares of the company's stock valued at $16,482,000 after buying an additional 651,800 shares in the last quarter. Armistice Capital LLC lifted its position in shares of Deciphera Pharmaceuticals by 12.7% during the 4th quarter. Armistice Capital LLC now owns 5,200,000 shares of the company's stock valued at $83,876,000 after buying an additional 588,000 shares in the last quarter. Goldman Sachs Group Inc. lifted its position in shares of Deciphera Pharmaceuticals by 14.4% during the 4th quarter. Goldman Sachs Group Inc. now owns 2,307,475 shares of the company's stock valued at $37,220,000 after buying an additional 290,968 shares in the last quarter. Deerfield Management Company L.P. Series C lifted its position in shares of Deciphera Pharmaceuticals by 2.8% during the 3rd quarter. Deerfield Management Company L.P. Series C now owns 6,897,606 shares of the company's stock valued at $87,738,000 after buying an additional 190,580 shares in the last quarter. Finally, Panagora Asset Management Inc. lifted its position in shares of Deciphera Pharmaceuticals by 157.1% during the 4th quarter. Panagora Asset Management Inc. now owns 235,845 shares of the company's stock valued at $3,804,000 after buying an additional 144,097 shares in the last quarter. Hedge funds and other institutional investors own 70.96% of the company's stock.

Analysts Set New Price Targets

DCPH has been the topic of a number of recent analyst reports. Jonestrading reiterated a "hold" rating and set a $25.60 target price on shares of Deciphera Pharmaceuticals in a research report on Monday, April 29th. Guggenheim reiterated a "neutral" rating on shares of Deciphera Pharmaceuticals in a research report on Tuesday, April 30th. Barclays raised Deciphera Pharmaceuticals from an "underweight" rating to an "equal weight" rating and increased their price objective for the company from $9.00 to $26.00 in a research note on Tuesday, April 30th. JMP Securities reissued a "market perform" rating on shares of Deciphera Pharmaceuticals in a research note on Tuesday, April 30th. Finally, Leerink Partnrs downgraded Deciphera Pharmaceuticals from an "outperform" rating to a "market perform" rating in a research note on Monday, April 29th. Seven research analysts have rated the stock with a hold rating and three have given a buy rating to the stock. According to MarketBeat, the stock has a consensus rating of "Hold" and a consensus price target of $24.17.

Deciphera Pharmaceuticals Stock Performance

Shares of DCPH remained flat at $25.59 during midday trading on Friday. The company's stock had a trading volume of 2,200 shares, compared to its average volume of 1,292,551. Deciphera Pharmaceuticals, Inc. has a twelve month low of $9.90 and a twelve month high of $25.61. The company has a market capitalization of $2.21 billion, a PE ratio of -11.58 and a beta of 0.19. The business has a fifty day simple moving average of $23.31 and a 200 day simple moving average of $18.23.

Deciphera Pharmaceuticals (NASDAQ:DCPH - Get Free Report) last issued its earnings results on Friday, May 10th. The company reported ($0.52) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.55) by $0.03. Deciphera Pharmaceuticals had a negative return on equity of 52.42% and a negative net margin of 108.86%. The business had revenue of $45.00 million during the quarter, compared to the consensus estimate of $45.99 million. On average, sell-side analysts predict that Deciphera Pharmaceuticals, Inc. will post -2.15 EPS for the current year.

About Deciphera Pharmaceuticals

Deciphera Pharmaceuticals, Inc, a biopharmaceutical company, develops drugs to enhance the lives of cancer patients by addressing key mechanisms of drug resistance that limit the rate and durability of response to existing cancer therapies in the United States and internationally. Its lead drug candidate is QINLOCK used for the treatment of gastrointestinal stromal tumors (GIST), as well as in INTRIGUE Phase 3 study to treat second-line GIST.